Piper Sandler Issues Pessimistic Forecast for Indivior (NASDAQ:INDV) Stock Price

Indivior (NASDAQ:INDV) had its price target reduced by research analysts at Piper Sandler from $16.00 to $13.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price would indicate a potential upside of 34.02% from the company’s previous close.

Several other analysts also recently weighed in on the company. Rodman & Renshaw began coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective for the company. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th.

Indivior Stock Down 1.9 %

Shares of INDV stock opened at $9.70 on Thursday. Indivior has a twelve month low of $7.33 and a twelve month high of $22.53. The company has a market cap of $1.34 billion, a P/E ratio of -27.71 and a beta of 0.82. The business has a fifty day simple moving average of $10.91 and a 200 day simple moving average of $10.60.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. As a group, equities research analysts anticipate that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Trading of Indivior

A number of hedge funds have recently made changes to their positions in INDV. GF Fund Management CO. LTD. acquired a new stake in shares of Indivior during the fourth quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Indivior in the fourth quarter worth approximately $56,000. Lazard Asset Management LLC acquired a new position in shares of Indivior in the fourth quarter worth approximately $57,000. Stifel Financial Corp acquired a new position in shares of Indivior in the third quarter worth approximately $100,000. Finally, Melqart Asset Management UK Ltd acquired a new position in shares of Indivior in the third quarter worth approximately $132,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.